Driving CAR T cell translation forward

Liora Schultz¹, Crystal Mackall^{2

3

4}

Affiliations

¹ Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
² Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA. cmackall@stanford.edu.
³ Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
⁴ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.

Review

Liora Schultz et al. Sci Transl Med. 2019.

. 2019 Feb 27;11(481):eaaw2127.

doi: 10.1126/scitranslmed.aaw2127.

Liora Schultz¹, Crystal Mackall^{2

3

4}

¹ Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
² Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA. cmackall@stanford.edu.
³ Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
⁴ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.

Abstract

Successes in CAR T cell translation have propelled their commercial launch, but expanding the impact of cancer immunotherapies remains challenging.